reference sequence (refseq) and annotations (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
90
Structured Review
Santa Cruz Biotechnology
reference sequence (refseq) and annotations
Reference Sequence (Refseq) And Annotations, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/reference+sequence+(refseq)+and+annotations/refseq/pmc11652270-59-0-11
Average 90 stars, based on 1 article reviews
Reference Sequence (Refseq) And Annotations, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/reference+sequence+(refseq)+and+annotations/refseq/pmc11652270-59-0-11
Average 90 stars, based on 1 article reviews
reference sequence (refseq) and annotations - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23). Article Snippet: Syed Khizer Hasan,* Gianluca Barba, Markus Metzler, Mariadomenica Divona, Tiziana Ottone, Laura Cicconi, Brunangelo Falini, Cristina Mecucci, and Francesco Lo-Coco Departmentof Biomedicine and Prevention,Universityof TorVergata,Rome,Italy Laboratorio di Neuro-Oncoematologia,Fondazione Santa Lucia,Rome,Italy Hematology Unit,Universityof Perugia,Polo Unico S.M.Misericordia,Perugia,Italy Departmentof Paediatrics,Universityof Erlangen-Nuremberg,Germany Institute of Hematology,Universityof Perugia,Perugia,Italy Article Title: Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. Article Snippet: Therapy-related acute leukemias (t-ALs) represent approximately 10–20% of all acute leukemias, are frequently resistant to chemotherapy, and are associated with guarded outcomes.. The national comprehensive cancer network data suggest that t-AL cases are diagnosed at increasing rates in breast cancer patients treated with chemotherapeutic agents targeting topoisomerase II.. Two cases of BRCA1-mutated ovarian and breast carcinoma who developed therapy-related APL and ALL, respectively, following topoisomerase II-directed therapy were characterized. Article Title: Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Article Snippet: Tiziana Ottone, Syed Khizer Hasan, Enrico Montefusco, Paola Curzi, Ashley N. Mays, Luciana Chessa, Antonella Ferrari, Esmeralda Conte, Nelida Inés Noguera, Serena Lavorgna, Emanuele Ammatuna, Mariadomenica Divona, Katia Bovetti, Sergio Amadori, David Grimwade, and Francesco Lo-Coco* Dipartimento di Biopatologia e Diagnostica per Immagini,University‘‘TorVergata,’’Rome,Italy Azienda Ospedaliera Sant’Andrea,University‘‘La Sapienza,’’Rome,Italy Dipartimento di Medicina di Laboratorio,PoliclinicoTorVergata,Rome,Italy Departmentof Medical and Molecular Genetics,King’s College London School of Medicine,London,UK |